HC Wainwright Has Weak Forecast for Rezolute FY2031 Earnings

Rezolute, Inc. (NASDAQ:RZLT) – Equities researchers at HC Wainwright cut their FY2031 earnings per share estimates for shares of Rezolute in a report issued on Friday, November 6th. HC Wainwright analyst D. Tsao now expects that the company will earn $2.82 per share for the year, down from their prior estimate of $2.94. HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Rezolute’s current full-year earnings is ($0.66) per share.

A number of other research analysts have also commented on the stock. Citigroup restated a “market outperform” rating on shares of Rezolute in a research report on Thursday, October 15th. Lake Street Capital increased their price objective on Rezolute from $9.00 to $12.00 and gave the stock a “buy” rating in a research report on Tuesday, October 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Rezolute in a research note on Thursday, October 15th. Zacks Research cut Rezolute from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 13th. Finally, Craig Hallum upgraded Rezolute from a “hold” rating to a “buy” rating and boosted their target price for the stock from $4.00 to $7.00 in a research report on Tuesday, September 29th. Twelve research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Rezolute has an average rating of “Moderate Buy” and an average target price of $11.22.

Rezolute Stock Performance

RZLT stock opened at $4.02 on Monday. The firm has a 50 day moving average of $4.11 and a 200-day moving average of $3.92. Rezolute has a 12 month low of $1.07 and a 12 month high of $11.16.

Rezolute (NASDAQ:RZLT) last issued its earnings results on Thursday, November 5th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.01.

Institutional Investors Weigh In On Rezolute

A number of institutional investors and hedge funds have recently bought and sold shares of RZLT. Auxano Advisors LLC purchased a new position in Rezolute in the 2nd quarter worth approximately $52,000. Sequoia Financial Advisors LLC bought a new position in shares of Rezolute in the 2nd quarter worth $75,000. WINTON GROUP Ltd purchased a new stake in shares of Rezolute during the 2nd quarter valued at $88,000. Integrated Wealth Concepts LLC purchased a new stake in shares of Rezolute during the 2nd quarter valued at $143,000. Finally, Y Intercept Hong Kong Ltd purchased a new stake in shares of Rezolute during the 1st quarter valued at $90,000. 82.97% of the stock is owned by hedge funds and other institutional investors.

More Rezolute News

Here are the key news stories impacting Rezolute this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $10 price target, signaling continued confidence despite lowering its forecasts. Rezolute analyst coverage
• Neutral Sentiment: A short-interest report stated that short interest was 0 shares as of November 10, despite describing it as a significant increase. The conflicting figures make the report difficult to interpret and offer no clear directional signal. Rezolute short-interest report
• Negative Sentiment: HC Wainwright cut its EPS estimates for fiscal 2027 through fiscal 2030, including deeper projected losses in FY2027–FY2029 and a lower FY2030 profit forecast ($1.30 versus $1.42). Lower earnings expectations could pressure sentiment, even though the analyst kept its Buy rating. HC Wainwright earnings estimate revisions

About Rezolute

Rezolute, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic diseases involving abnormal insulin activity. The company’s lead product candidate is RZ358, also known as ersodetug, an investigational monoclonal antibody designed to reduce the effects of excessive insulin by binding to an allosteric site on the insulin receptor. RZ358 is being developed primarily for the treatment of congenital hyperinsulinism, a rare disorder in which the pancreas releases too much insulin, causing potentially severe and recurrent hypoglycemia.